期刊
JOURNAL OF MEDICAL GENETICS
卷 42, 期 7, 页码 602-603出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jmg.2004.024133
关键词
-
资金
- NCI NIH HHS [1R01 CA81203, 1R01 CA63682] Funding Source: Medline
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据